Endocrine Pharmacology Practice Questions

Q: Which steroid has the least mineralocorticoid activity?

Methylprednisolone. **Explanation:** The correct answer is **Methylprednisolone**. The classification of corticosteroids is based on their relative **glucocorticoid** (anti-inflammatory) and **mineralocorticoid** (salt-retaining) potencies. Glucocorticoids exert their mineralocorticoid effects by binding to aldosterone receptors in the renal distal tubules, leading to sodium retention and potassium excretion. * **Methylprednisolone:** This is a synthetic intermediate-acting glucocorticoid. It has been chemically modified to enhance anti-inflammatory potency while significantly reducing mineralocorticoid activity. Its salt-retaining potency is near zero (0.5 compared to Hydrocortisone's 1), making it the correct choice among the options. **Analysis of Incorrect Options:** * **Aldosterone:** The primary endogenous mineralocorticoid. It has maximal salt-retaining activity and negligible anti-inflammatory effects. * **Deoxycorticosterone acetate (DOCA):** A precursor of aldosterone. It is a pure mineralocorticoid used experimentally to induce hypertension; it lacks glucocorticoid activity. * **Hydrocortisone (Cortisol):** The main endogenous glucocorticoid. It possesses significant mineralocorticoid activity (ratio of 1:1). It is often avoided in patients where fluid retention is a concern (e.g., heart failure or hypertension). **NEET-PG High-Yield Pearls:** * **Dexamethasone & Betamethasone:** These are long-acting steroids with **zero** mineralocorticoid activity. If they were an option, they would be "less" than methylprednisolone. * **Fludrocortisone:** A synthetic steroid with the highest mineralocorticoid-to-glucocorticoid ratio used clinically (primarily for Addison’s disease). * **Mnemonic for Potency (Least to Most):** **C**ortisol < **P**rednisolone < **M**ethylprednisolone < **D**examethasone (**C**an **P**eter **M**ake **D**inner).

Q: Which of the following are uses of danazol?

All of the above. **Explanation:** **Danazol** is a synthetic ethisterone derivative with a complex pharmacological profile. It acts as a **weak androgen** and a **gonadotropin inhibitor**, creating a "pseudo-menopausal" state by suppressing the pituitary-ovarian axis (inhibiting LH and FSH surges). **Why "All of the Above" is Correct:** 1. **Endometriosis (Option A):** This is the primary clinical use. Danazol causes atrophy of ectopic endometrial tissue by inhibiting steroidogenesis and creating a hypoestrogenic, hyperandrogenic environment. 2. **Menorrhagia (Option B):** By suppressing the endometrial lining and inducing amenorrhea, it is effective in reducing heavy menstrual bleeding, particularly when associated with fibroids or dysfunctional uterine bleeding. 3. **Hereditary Angioneurotic Edema (HANE) (Option C):** This is a high-yield indication. Danazol increases the hepatic synthesis of the **C1 esterase inhibitor** protein, which is deficient in patients with HANE, thereby preventing attacks. **Clinical Pearls for NEET-PG:** * **Mechanism:** It is a "selective pituitary gonadotropin inhibitor" and also directly inhibits several enzymes involved in adrenal and gonadal steroidogenesis. * **Side Effects:** Due to its androgenic nature, it commonly causes **weight gain, acne, hirsutism, deepening of the voice, and decreased breast size.** * **Contraindications:** It should be avoided in pregnancy (teratogenic—causes virilization of female fetuses) and in patients with significant hepatic dysfunction. * **Other Uses:** It is occasionally used in **Fibrocystic Breast Disease** and **Immune Thrombocytopenic Purpura (ITP)**.

Q: Which of the following is not a starting criterion for sulfonylurea therapy?

Total pancreatectomy. ### Explanation **1. Why "Total Pancreatectomy" is the Correct Answer:** Sulfonylureas (e.g., Glibenclamide, Glimepiride) are **insulin secretagogues** [1], [3]. Their primary mechanism of action involves binding to the SUR1 subunit of ATP-sensitive potassium channels on the **pancreatic beta cells** [1], [3]. This leads to cell depolarization, calcium influx, and the subsequent release of pre-formed insulin [3]. In a patient who has undergone a **total pancreatectomy**, there are no functional beta cells remaining. Since sulfonylureas require endogenous insulin stores to function, they are absolutely ineffective and contraindicated in this scenario. These patients have "surgical diabetes" and require lifelong exogenous insulin therapy. **2. Analysis of Incorrect Options:** * **B. Non-insulin-dependent diabetes mellitus (NIDDM):** This is the primary indication for sulfonylureas [1]. In Type 2 DM, beta cells are still functional but often sluggish; sulfonylureas help "kickstart" insulin secretion. * **C. Diabetes diagnosed after 40-60 years of age:** Sulfonylureas are most effective in patients who develop diabetes later in life (maturity-onset). A diagnosis after age 40, a duration of disease less than 5 years, and a daily insulin requirement of less than 40 units are traditional predictors of a good response to sulfonylureas. **3. NEET-PG High-Yield Pearls:** * **Mechanism:** Blocks $K_{ATP}$ channels $\rightarrow$ Depolarization $\rightarrow$ $Ca^{2+}$ influx $\rightarrow$ Insulin release [3]. * **Primary Side Effect:** Hypoglycemia (most common with Glyburide/Glibenclamide due to long half-life) and weight gain [2]. * **Disulfiram-like reaction:** Classically associated with first-generation sulfonylureas like **Chlorpropamide**. * **Failure Criteria:** "Primary failure" occurs if the drug never works; "Secondary failure" occurs when beta-cell function declines over years of treatment, eventually requiring insulin [1].

Q: Cabergoline is the drug of choice for which condition?

Prolactinoma. **Explanation:** **Correct Answer: C. Prolactinoma** **Mechanism and Rationale:** Cabergoline is a potent, long-acting **ergot-derived Dopamine (D2) receptor agonist** [1]. In the anterior pituitary, dopamine acts as the primary inhibitory factor for prolactin secretion. By stimulating D2 receptors on lactotrophs, Cabergoline effectively suppresses prolactin synthesis and release. It is considered the **Drug of Choice (DOC)** for prolactinomas because it is more effective at shrinking tumor size and normalizing prolactin levels compared to Bromocriptine, with the added benefit of a better side-effect profile and a longer half-life (allowing for once or twice weekly dosing) [1], [2]. **Analysis of Incorrect Options:** * **A. Parkinsonism:** While dopamine agonists (like Bromocriptine, Pramipexole, or Ropinirole) are used in Parkinson’s, Cabergoline is rarely used today for this indication due to the risk of **cardiac valvular fibrosis** at the high doses required for motor symptoms. * **B. Alzheimer’s Disease:** This condition is characterized by a cholinergic deficit. Treatment involves cholinesterase inhibitors (Donepezil) or NMDA antagonists (Memantine), not dopamine agonists. * **D. Galactorrhea:** While Cabergoline treats galactorrhea, the question asks for the specific clinical *condition*. Galactorrhea is a *symptom* often caused by a prolactinoma. In the context of NEET-PG, always prioritize the definitive pathological diagnosis (Prolactinoma) over the clinical sign. **High-Yield Clinical Pearls for NEET-PG:** * **Half-life:** Cabergoline has a very long half-life (~65 hours), enabling weekly dosing [1]. * **Side Effects:** Nausea and orthostatic hypotension are common. Long-term high-dose use requires monitoring for cardiac valvulopathy via echocardiography [3]. * **Pregnancy:** Bromocriptine is generally preferred if pregnancy is desired due to a longer track record of safety data, though Cabergoline is increasingly used.

Q: All of the following statements about nateglinide are true except?

It decreases insulin resistance. **Explanation:** **Nateglinide** belongs to the **Meglitinide (Glinide)** class of oral hypoglycemic agents. The core mechanism of this class is the stimulation of insulin secretion from the pancreas, making them **insulin secretagogues**, not insulin sensitizers. 1. **Why Option C is the correct answer (False statement):** Nateglinide does **not** decrease insulin resistance. Drugs that decrease insulin resistance (insulin sensitizers) include Biguanides (Metformin) and Thiazolidinediones (Pioglitazone). Nateglinide works solely by increasing the output of insulin from functional pancreatic beta cells. 2. **Analysis of other options:** * **Option A (True):** Nateglinide has a very rapid onset and short duration of action. It is specifically taken just before meals to mimic the first-phase insulin response, effectively controlling **post-prandial hyperglycemia**. * **Option B (True):** Because of its short half-life and "quick-on, quick-off" action, the risk of delayed or prolonged **hypoglycemia is significantly lower** compared to long-acting sulfonylureas (like Glibenclamide). * **Option D (True):** Like sulfonylureas, nateglinide binds to the **SUR1 receptor** on the ATP-sensitive $K^+$ channels of pancreatic $\beta$-cells, causing channel closure, depolarization, $Ca^{2+}$ influx, and subsequent **insulin release**. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Closes ATP-sensitive $K^+$ channels (distinct binding site from sulfonylureas). * **Metabolism:** Primarily metabolized by the liver; it is safer than sulfonylureas in patients with mild-to-moderate renal impairment. * **Dosing:** Known as "post-prandial glucose regulators"; if a meal is skipped, the dose must be skipped to avoid hypoglycemia. * **Weight Gain:** Like all secretagogues, nateglinide can cause modest weight gain.

Q: What is the drug of choice for managing hyperglycemia in diabetic ketoacidosis?

Regular insulin. **Explanation:** **1. Why Regular Insulin is the Correct Answer:** Regular insulin (Short-acting) is the drug of choice for Diabetic Ketoacidosis (DKA) because it is the **only** insulin formulation that can be administered **intravenously (IV)**. In DKA, there is severe dehydration and poor peripheral perfusion, making subcutaneous absorption unpredictable. IV administration ensures 100% bioavailability and a rapid onset of action. Its short half-life (approx. 5–10 minutes when given IV) allows for precise titration based on hourly blood glucose monitoring, minimizing the risk of sudden hypoglycemia or cerebral edema. **2. Why Other Options are Incorrect:** * **Lente insulin:** This is an intermediate-acting insulin. It has a slow onset and prolonged duration, making it unsuitable for the acute, minute-to-minute management required in DKA. * **Glyburide:** This is a second-generation Sulfonylurea (oral hypoglycemic). It works by stimulating pancreatic beta cells to release insulin. In DKA, there is an absolute or relative insulin deficiency and severe metabolic derangement that oral agents cannot correct. * **70/30 insulin:** This is a premixed combination (70% NPH, 30% Regular). Because it contains NPH (intermediate-acting), it cannot be given intravenously and is used for chronic maintenance, not emergencies. **3. High-Yield Clinical Pearls for NEET-PG:** * **Route:** In DKA, Regular insulin is given as a continuous low-dose IV infusion (0.1 units/kg/hour). * **Potassium Warning:** Always check potassium levels before starting insulin. Insulin shifts $K^+$ into cells; if the patient is hypokalemic ($<3.3$ mEq/L), starting insulin can cause fatal arrhythmias. * **The Goal:** The primary goal of insulin in DKA is not just to lower glucose, but to **stop ketogenesis** by inhibiting hormone-sensitive lipase. * **Switching:** Transition to subcutaneous insulin only when the anion gap has closed and the patient is able to eat.

Q: What is the primary route of administration for GnRH analogues?

Subcutaneous. **Explanation:** **1. Why Subcutaneous is Correct:** GnRH (Gonadotropin-Releasing Hormone) analogues, such as **Leuprolide, Goserelin, and Nafarelin**, are synthetic decapeptides. Because they are peptides, they are susceptible to rapid degradation by proteolytic enzymes in the gastrointestinal tract if taken orally. The **subcutaneous (SC)** route is preferred because it allows for the formulation of **depot preparations**. These depots provide a sustained, slow release of the drug over weeks or months, which is essential for achieving the therapeutic goal of "medical castration" (downregulation of GnRH receptors to suppress FSH and LH). **2. Why Other Options are Incorrect:** * **Oral:** As mentioned, GnRH analogues are peptides. They have poor bioavailability due to gastric acid degradation and first-pass metabolism. * **Intravenous (IV):** While possible, the IV route results in a very short half-life (minutes) and lacks the sustained-release profile required for chronic conditions like prostate cancer or endometriosis. * **Transdermal:** The large molecular size and hydrophilic nature of these peptides make them unsuitable for passive diffusion through the skin barrier. **3. Clinical Pearls for NEET-PG:** * **Biphasic Action:** Initial administration causes a "flare-up" (transient increase in LH/FSH), followed by downregulation and desensitization of pituitary GnRH receptors. * **Alternative Route:** **Intranasal** administration (e.g., Nafarelin) is used for shorter-term indications like endometriosis or precocious puberty, though SC remains the primary route for long-term therapy. * **Therapeutic Uses:** Prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. * **Antagonists vs. Agonists:** Unlike analogues (agonists), GnRH **antagonists** (e.g., Degarelix, Cetrorelix) produce immediate suppression without the initial flare-up.

Q: All of the following are side effects of steroids except?

Osteomalacia. **Explanation:** The correct answer is **Osteomalacia** because glucocorticoids (steroids) cause **Osteoporosis**, not osteomalacia. 1. **Why Osteomalacia is incorrect:** Osteomalacia is a defect in bone *mineralization* (soft bones), usually due to Vitamin D deficiency. Steroids, however, cause a decrease in bone *density* (brittle bones) by inhibiting osteoblast activity, stimulating osteoclasts, and decreasing intestinal calcium absorption. This leads to **Osteoporosis** and an increased risk of avascular necrosis of the femoral head. 2. **Analysis of other options:** * **Hyperglycemia:** Steroids are "diabetogenic." They increase gluconeogenesis in the liver and decrease peripheral glucose uptake (insulin resistance), often leading to steroid-induced diabetes. * **Infection:** Steroids are potent immunosuppressants. They inhibit NF-κB, decrease cytokine production (IL-1, IL-2), and cause lymphopenia, masking signs of inflammation and increasing susceptibility to opportunistic infections (e.g., Tuberculosis reactivation). * **Peptic Ulcer:** Steroids inhibit phospholipase A2, reducing protective prostaglandins in the gastric mucosa. When used with NSAIDs, the risk of peptic ulceration and perforation increases significantly. **Clinical Pearls for NEET-PG:** * **Mnemonic for Steroid Side Effects:** "CUSHINGOID" (Cataracts, Ulcers, Striae/Skin thinning, Hypertension, Immunosuppression, Necrosis of femoral head, Glucose elevation, Osteoporosis, Impaired wound healing, Depression/Psychosis). * **Ocular effects:** Steroids cause **posterior subcapsular cataracts** and can increase intraocular pressure (glaucoma). * **Growth:** In children, they cause growth retardation due to premature closure of epiphyseal plates.

Question 1

Which steroid has the least mineralocorticoid activity?

Accepted Answer

Methylprednisolone

Answer

Aldosterone

Answer

Deoxycorticosterone acetate (DOCA)

Answer

Hydrocortisone

Question 2

Which of the following are uses of danazol?

Accepted Answer

All of the above

Answer

Endometriosis

Answer

Menorrhagia

Answer

Hereditary angioneurotic edema

Question 3

Paricalcitol is FDA-approved for which of the following conditions?

Accepted Answer

Secondary hyperparathyroidism

Answer

Rickets

Answer

Osteomalacia

Answer

Primary hyperparathyroidism

Question 4

Which of the following is not a starting criterion for sulfonylurea therapy?

Accepted Answer

Total pancreatectomy

Answer

Non-insulin-dependent diabetes mellitus (NIDDM)

Answer

Diabetes diagnosed after 60 years of age

Answer

None of the above

Question 5

Cabergoline is the drug of choice for which condition?

Accepted Answer

Prolactinoma

Answer

Parkinsonism

Answer

Alzheimer's disease

Answer

Galactorrhea

Question 6

A 30-year-old female with a 15-year history of asthma presents to the emergency room with left elbow pain. Physical examination reveals tenderness and swelling over the olecranon process. An X-ray of the left arm reveals a fracture. Her medications include oral prednisone and albuterol aerosol. By which of the following mechanisms might corticosteroids have contributed to her fracture?

Accepted Answer

Increased osteoclastic bone resorption and decreased osteoblastic bone formation

Answer

Decreased osteoblastic bone formation only

Answer

Decreased osteoblastic bone formation and osteoclastic bone resorption

Answer

Increased osteoclastic bone resorption only

Question 7

All of the following statements about nateglinide are true except?

Accepted Answer

It decreases insulin resistance

Answer

Decreases post-prandial hyperglycemia

Answer

Hypoglycemia is less common than with sulfonylureas

Answer

It acts by releasing insulin

Question 8

What is the drug of choice for managing hyperglycemia in diabetic ketoacidosis?

Accepted Answer

Regular insulin

Answer

Lente insulin

Answer

Glyburide

Answer

70/30 insulin

Question 9

What is the primary route of administration for GnRH analogues?

Accepted Answer

Subcutaneous

Answer

Oral

Answer

Intravenous

Answer

Transdermal

Question 10

All of the following are side effects of steroids except?

Accepted Answer

Osteomalacia

Answer

Hyperglycemia

Answer

Infection

Answer

Peptic ulcer

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?